The European experience of ACURATE neo in bicuspid and tricuspid aortic valves

The magazine EuroIntervention (EuroIntervention 2018; Jaa-467 2018, doi: 10.4244/EIJ-D-18-00281) publishes encouraging results about safety and feasibility of traetment of bicuspid aortic valves with the TAVI aortic valve ACURATE neo (Boston Scientific). The outcomes have been collected by a multicenter retrospective and not randomized study about European experience of ACURATE neo in bicuspid (BAV) and tricuspid (AV) valves which has enrolled 712 patients in Europe (of which the 7.5% are bicuspids) and has involved in Italy the healthcare centers S. Raffaele, Humanitas, Lancisi, Ferrarotto.


The outcomes

The clinical endpoints show results in bicuspids compare with tricuspids:

  • Pre dilatation (BAV 94.4% vs. AV 66.6%)1
  • PVL £ mild (BAV 92.6% vs. AV 94.5%)1,2
  • Stroke at 30-days (BAV 7.4% vs. AV 3.7%)1
  • Medium gradient (BAV 9.8±4.2 mmHg vs. AV 9.9±4.5 mmHg) 1
  • No differences were observed in the rate of pacemaker implant and of other factors (mortality, rehospitalisation, vascular complications)

1 propensity score matching (PSM)

difference not statistically significant after PSM



This study demonstrates that the ACURATE neo implant in bicuspids provides comparable clinical outcomes with those from use in patients with a tricuspid aortic valve

acurate neo eurointervention


The ACURATE neo vale is a minimally invasive transcatheter aortic valve implantation (TAVI) device. Composed of a self-expanding nitinol stent and porcine pericardial skirt, ACURATE neo is designed in order to facilitate the axial self-alignment of the bioprosthesis.

Visit the magazine website